Humanin Peptide: Benefits, Research Dosing, and Safety

Think of your mitochondria as power plants that can send radio messages. When the cell comes under stress, the plant broadcasts a short signal that tells nearby machinery to hold the line instead of self-destructing. Humanin is one of those broadcasts.

Literally stated: humanin is a micropeptide encoded within the 16S ribosomal RNA gene of mitochondrial DNA, released by cells under stress, and it inhibits apoptosis, the programmed cell-death cascade. Researchers in Japan found it in 2001 while studying why some neurons in an Alzheimer's-affected brain refused to die (Hashimoto et al., PNAS, 2001, PMID 11371646).

That origin matters for one practical reason. Humanin belongs to the same family as MOTS-c and the SHLP peptides, all encoded by mitochondrial DNA rather than the nuclear genome. Circulating levels decline with age, which is why the longevity field watches this family closely.

Most vials sold as humanin are actually HNG (S14G-humanin), a lab-modified analog roughly 1,000 times more potent in cell studies than the natural sequence (Gao et al., 2017, PMID 29043002). Check which form a listing describes before you compare any numbers.

Both peptides come from mitochondrial DNA, and vendors often shelve them together. The research profiles are not interchangeable.

MOTS-c is the sibling with actual usage history on this site: dosing conventions are documented in the MOTS-c dosage guide, cycle patterns in MOTS-c cycle length, and user-reported outcomes in MOTS-c before and after. Humanin has none of that accumulated practice.

If your goal is metabolic (fat loss, insulin sensitivity, endurance), the evidence weight sits with MOTS-c. Humanin's case is cellular protection, and that case is still preclinical. For mitochondrial support aimed at muscle and performance, SS-31 comes up in bodybuilding contexts with the same caveat: promising mechanism, thin human data.

The honest summary: strong, consistent results in cells and rodents, and essentially nothing in supplemented humans.

The foundational work showed humanin rescuing neurons from death triggered by familial Alzheimer's genes and amyloid-beta toxicity (Hashimoto et al., 2001, PMID 11371646), with follow-up characterization across a wide range of Alzheimer's-relevant insults the same year (PMID 11717357). The potent HNG analog extended these findings to stroke-model neuroprotection and cardiac protection in animal studies (PMID 29043002).

A 2025 review of mitochondrial-derived peptides in neurodegenerative disease sums up the current position: mechanisms are increasingly mapped, therapeutic potential is real, and clinical translation has not happened (Thakur et al., Molecular Neurobiology, 2025, PMID 40715951).

What is missing is the part that matters for anyone holding a vial. No completed human trial has tested injected humanin for cognition, longevity, or anything else. No dose-ranging study exists. Observational studies correlate higher natural humanin levels with better outcomes, and correlation in blood work does not validate injection protocols.

Animal studies dose humanin by weight, typically intraperitoneal injections in the low mg/kg range for rodents. Converting a mouse IP dose to a human subcutaneous dose involves surface-area math, absorption differences, and assumptions no one has verified. Every human number below is community practice, not evidence.

Run the danger math before touching any of it. A 10 mg vial reconstituted with 1 mL of bacteriostatic water yields 10 mg/mL, so 10 units on an insulin syringe delivers 1 mg. Draw 50 units because a MOTS-c habit taught you that volume, and you inject 5 mg, the top of the reported range, on day one. The fix is the same as every peptide: run the reconstitution calculator and label the vial before the first draw.

The potency trap is worse. If a product is HNG rather than natural-sequence humanin, its cell-study potency runs roughly 1,000-fold higher. Treating the two as interchangeable means your "conservative" dose can be three orders of magnitude off on activity. The general procedure for handling any lyophilized peptide is covered in how to reconstitute a peptide and how to inject peptides.

No human safety database exists for humanin supplementation. That sentence is the whole side-effect profile, and it cuts both ways: no documented harms, and no documented absence of harm.

Two mechanistic flags deserve respect. First, humanin interacts with the IGF-1 axis by binding IGFBP-3, and long-term manipulation of growth-factor signaling is exactly the kind of intervention that needs trial data before chronic use. Second, an anti-apoptotic agent protects cells indiscriminately in principle; apoptosis is also how the body removes damaged and precancerous cells. Whether exogenous humanin meaningfully blunts that surveillance in humans is unknown, and unknown is the point.

Quantify the exposure gap: MOTS-c users can lean on several years of community usage and early human data, summarized in MOTS-c side effects. Humanin users have zero published human supplementation-years. Anyone injecting it is the experiment.

If you proceed anyway as a research matter, the harm-reduction basics in the peptide safety guide apply: sterile technique, single-compound introduction, conservative start, and documented response. Injection-site practice mirrors where to inject MOTS-c: rotate subcutaneous sites, abdomen or thigh.